Abstract:γ-Aminobutyric acid (GABA) is the most prevalent inhibitory neurotransmitter in the mammalian brain and has been found to play an important role in the pathogenesis or the expression of many neurological diseases, including epilepsy. Although GABA can act on different receptor subtypes, the component of the GABA system that is most critical to modulation of seizure activity is the GABA A -receptor-chloride (Cl − ) channel complex, which controls the movement of Cl − ions across the neuronal membrane. In the mature brain, binding of GABA to GABA A receptors evokes a hyperpolarising (anticonvulsant) response, which is mediated by influx of Cl − into the cell driven by its concentration gradient between extracellular and intracellular fluid. However, in the immature brain and under certain pathological conditions, GABA can exert a paradoxical depolarising (proconvulsant) effect as a result of an efflux of chloride from high intracellular to lower extracellular Cl − levels. Extensive preclinical and clinical evidence indicates that alterations in GABAergic inhibition caused by drugs, toxins, gene defects or other disease states (including seizures themselves) play a causative or contributing role in facilitating or maintaning seizure activity. Conversely, enhancement of GABAergic transmission through pharmacological modulation of the GABA system is a major mechanism by which different antiseizure medications exert their therapeutic effect. In this article, we review the pharmacology and function of the GABA system and its perturbation in seizure disorders, and highlight how improved understanding of this system offers opportunities to develop more efficacious and better tolerated antiseizure medications. We also review the available data for the two most recently approved antiseizure medications that act, at least in part, through GABAergic mechanisms, namely cenobamate and ganaxolone. Differences in the mode of drug discovery, pharmacological profile, pharmacokinetic properties, drug–drug interaction potential, and clinical efficacy and tolerability of these agents are discussed.

Excitatory Amino Acids in Epilepsy

The Role of Glutamate Receptors in Epilepsy

Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy

Metabotropic glutamate receptors (mGluRs) in epileptogenesis: an update on abnormal mGluRs signaling and its therapeutic implications

Central Histaminergic Signalling, Neural Excitability and Epilepsy

Altered Glutamate Metabolism Contributes to Antiepileptogenic Effects in the Progression from Focal Seizure to Generalized Seizure by Low-Frequency Stimulation in the Ventral Hippocampus

Glutamate Receptor As Target for Drug Therapy in Epilepsy

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept

Network-Related Changes in Neurotransmitters and Seizure Propagation During Rodent Epileptogenesis

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System

Revisiting the role of neurotransmitters in epilepsy: An updated review

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

Advanced Molecular Mechanisms of Epilepsy

Adrenergic receptor system as a pharmacological target in the treatment of epilepsy (Review)

Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs

Decoding Epileptic Seizures: Exploring In Vitro Approaches to Unravel Pathophysiology and Propel Future Therapeutic Breakthroughs

Cholinergic Signaling, Neural Excitability, and Epilepsy

Regulation of Inhibitory Signaling at the Receptor and Cellular Level; Advances in Our Understanding of GABAergic Neurotransmission and the Mechanisms by Which It Is Disrupted in Epilepsy

The Potential Role of Polyamines in Epilepsy and Epilepsy-Related Pathophysiological Changes

Astrocytes and Glutamine Synthetase in Epileptogenesis

5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy